CHAIR
:
SPEAKER
(S):
Pete Mooney, National Practice Director for Life Sciences, Deloitte Consulting LLP
Tom Polen, Senior Director, Marketing, Baxter Healthcare
Scott Gottlieb, MD, Resident Fellow, American Enterprise Institute
Paul Marshall, Vice President, Operations, Amylin
Description
As the biologics market continues its rapid growth rate, and the eventual approval of biosimilars brings a new form of competition, companies need to further differentiate their products and decide how to supply the global market. Today, many options are
Objectives:
Bring a "360-degree" perspective to decisions, including the viewpoints of the rapidly growing biopharma company, the mature biopharma manufacturer, the experienced contract manufacturer and the global outsourcer.
Look at such provocative issues as: "Make or Buy," "All or Nothing," "Here or There" and "Product Lifecycle Management."